Company Profile
Nanospectra Biosciences, Inc.
Cancer
Imaging
8285 El Rio Street, Suite 150
Houston, TX 77054
USA
www.nanospectra.com
|
Incorporated in 2001
14 Employees
|
Privately Held
|
|
This Year's Highlights
- Filed IDE for head and neck cancer in 2007.
- Completed Series A and State of Texas investment totalling $4 million in 2006-2007.
- COmpleted manufacturing facility for clinical trials.
|
Anticipated Highlights
- Pilot clinical trial in recurrent and refractory head and neck cancers to commence Q4-07 to Q1-08
- Filing IDE for safety/dosing study in prostate cancer
- Series B to fund pivotal trial.
|
|
Corporate Mission
Nanospectra Biosciences (NBI) is developing minimally invasive photo-thermal cancer therapies for solid tumors using its proprietary AuroShell(TM) particles. Our optically-tunable particles are delivered intravenously, activated by a non-thermal laser and destroy solid tumors and related neo-vasculature without damage to healthy tissue.
Although our particle-based photo-thermal therapy is broadly applicable to nearly all solid tumors, we will initially test our therapy in head and neck cancers. An IDE for recurrent and refractory head and neck cancer was filed in 2007.
The advantages of our therapy include: (i) achieving a rapid complete or partial response detectable by the physician within days; (ii) treating early regional metastatic disease before clinical detection; and (iii) remaining compatible with, and potentially enhancing, standard chemotherapy and radiation treatment modalities.
NBI is advised by a group of world-class researchers and experienced biotech entrepreneurs and has secured peer-reviewed grants and awards totaling $5.4 million to develop its technology for cancer treatment and diagnosis and for other applications.
|
